New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation?


PURPOSE OF REVIEW The continuing problem of late graft loss and immunosuppressive drug toxicity forces us to explore new treatments for the induction of transplant tolerance. Monoclonal antibodies targeting molecules implicated in lymphocyte activation, in particular CD3/TCR, constitute a promising strategy. RECENT FINDINGS Promising results were obtained… (More)
DOI: 10.1097/MOT.0b013e3283402bd8


  • Presentations referencing similar topics